ImpediMed (ASX:IPD) said a US-health insurer has recognized the company's bioimpedance spectroscopy technology as medically necessary to assess lymphedema, according to a Thursday filing with the Australian bourse.
The recognition will support reimbursement for lymphedema testing using the company's digital health platform, the filing said.
Shares of the company rose 19% in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.